Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Transforming Seborrheic Dermatitis and Rosacea Treatments
Description
In this presentation, Benjamin Anger discusses advancements in the understanding and treatment of seborrheic dermatitis and rosacea, two inflammatory skin conditions that remain under-researched in terms of their pathophysiology and effective treatments. He highlights how seborrheic dermatitis commonly affects areas with high sebaceous glands, presenting significant quality of life impacts, especially in various populations including those with skin of color. Anger emphasizes the need for better understanding of its immune dysregulation, particularly noting its TH-17 skewed profile. Recent developments in treatment, such as Rifluma less foam, indicate progress, yet highlight a need for further innovations, particularly for moderate to severe cases. Transitioning to rosacea, Anger outlines its complexities, characterized by various phenotypes, and the persistent impact it has on patients' well-being. The pathophysiology of rosacea involves innate immune activation and TH-1/TH-17 upregulation, with potential links to various comorbidities. Despite existing treatments, there remains a significant gap in effective therapies for persistent erythema, underscoring the necessity for continued research into personalized treatment strategies that address the diverse manifestations and underlying mechanisms of these skin diseases.
View moreConclusions
- Seborrheic dermatitis (SD) and rosacea are prevalent conditions that require more research to understand their treatment effects and disease mechanisms.
- There's a significant lack of understanding regarding the pathology and pathogenesis of seborrheic dermatitis and rosacea.
- Seborrheic dermatitis occurs commonly in areas with a high concentration of sebaceous glands, affecting mainly the face and scalp.
- The worldwide prevalence of seborrheic dermatitis is estimated at about 5%, with some studies suggesting up to 10% affect the adult population.
- Seborrheic dermatitis is often associated with rosacea and neurological conditions such as Parkinson's disease and HIV, suggesting shared mechanisms in their pathology.
- The immunological profile of seborrheic dermatitis shows a predominant TH-17 skew with alterations in cytokine levels and skin barrier integrity.
- Recent advances using transcriptomic profiling have revealed immune and lipid dysregulation in seborrheic dermatitis, proposing a more complex inflammatory mechanism than previously understood.
- There is a critical need for more effective and long-term treatment options for seborrheic dermatitis and rosacea, particularly approaches that do not exacerbate existing conditions.
- Understanding the pathomechanisms of these diseases can lead to the development of novel treatment strategies and improved patient outcomes.
- Research into seborrheic dermatitis and rosacea highlights the necessity of personalized treatment approaches based on individual disease profiles.
- Adalsteinsson et al., An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020 May;29(5):481-489
- Gupta et al., Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. Am J Clin Dermatol. 2017 Apr;18(2):193-213.
- Tucker et al. Seborrheic Dermatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-
- Veraldi, et al. Seborrheic dermatitis and anti-COVID-19 mask. J Cosmet Dermatol. 2020 Oct;19(10):2464-2465
- Schwartz, et al. Seborrheic dermatitis: an overview. Am Fam Physician. 2006 Jul 1;74(1):125-30
- Naldi et al., Seborrhoeic dermatitis of the scalp. BMJ Clin Evid. 2015 May 27;2015:1713
- Bickers et al., The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006 Sep;55(3):490-500
- Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol. 2009 Nov-Dec;27(6 Suppl):S48-53.
- Blauvelt, et al., Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: Assessment of pruritus. Presented at AAD 2023.
- Ghalili et al., IL-12/23-targeting in seborrheic dermatitis patients leads to long-lasting response. Arch Dermatol Res. 2023 Dec;315(10):2937-2940.
- van Zuuren, et al. Rosacea: New Concepts in Classification and Treatment. Am J Clin Dermatol. 2021 Jul;22(4):457-465
- Huynh, et al. Burden of Disease: The Psychosocial Impact of Rosacea on a Patient's Quality of Life. Am Health Drug Benefits. 2013 Jul;6(6):348-54.
- Barakii YA, et al., Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022 Jun 1;158(6):617-625.
- Gether L, et al., Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018 Aug;179(2):282-289.
- Gur TF, et al. The investigation of the relationships of demodex density with inflammatory response and oxidative stress in rosacea. Arch Dermatol Res. 2018 Nov;310(9):759-767.
- Wang, et al. Multi-Transcriptomic Analysis and Experimental Validation Implicate a Central Role of STAT3 in Skin Barrier Dysfunction Induced Aggravation of Rosacea. Inflamm Res. 2022 Mar 31;15:2141-2156.